Enveric Biosciences announces the filing of its 10th patent application for its tryptamine-based molecules.
Psychedelics
Novamind Reports Fiscal Q2 2022 Financial Results and Operating Highlights
Novamind reports 32% q-o-q revenue growth, up to CAD $2.45 million in its latest quarter. Cash balance of ~CAD$8 million including post-period financing.
Mydecine Reports Positive Pre-IND Meeting With FDA For MYCO-001 Smoking Cessation Study
Mydecine prepares to submit its IND and application for Breakthrough Therapy Status for smoking cessation after successful meeting with FDA.
Red Light Holland Reports Fiscal Third Quarter Results
Red Light Holland reports quarterly revenue growth of 28% and gross profit growth of 48% for Q3 of fiscal 2022. Strong cash position of CAD$27.3 million.
Revitalist Receives Approval from Biomedical Research Alliance of New York Permitting the Company to Perform Human Subjects Clinical Trials
Revitalist obtains regulatory approval for its clinics to host human clinical trials for psychedelics-based therapies.
Why Microdosing Cannot Replace Psychedelic Medicine
Psychedelic medicine is proving it can provide spectacular treatment results for many mental health disorders. Microdosing may also be an important therapy tool. But there's a catch.
COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights
COMPASS Pathways reported its financial results for the fourth quarter and full year 2021 and gave an update on recent progress across its business.
Pasithea Therapeutics Announces Plans to Open Three New Clinics in the UK by Mid-2022
Pasiethea Therapeutics plans to offer three new clinics offering both ketamine-based and "repeated transcranial magnetic stmulation" treatments (rTMS).
Optimi Health Launches E-Commerce Platform Featuring All-Natural Functional Mushroom Supplements
Optimi Health announces the launch of six nootropic supplements derived from functional mushrooms.
The Future of Psychedelic Medicine: Two DIFFERENT Treatment Models
Spiritual journey or clinical therapy? What does the future of psychedelic medicine look like?
PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation
Pharmather announces a method of use and composition of matter patent from the USPTO for its proprietary ketamine formulation, KETABET(TM).
Mindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through its COPE Program with InterVivo Solutions
Mindset announces new insights in research on psychedelics molecules via its COPE initiative.
Optimi Health Approved to Supply Psilocybin Under Health Canada’s Special Access Program
Optimi Health's subsidiary has been named an approved supplier of psilocybin for Health Canada's SAP access program.
Field Trip Health Ltd. Reports Third Fiscal Quarter 2022 Financial Results and Provides Business Update
During the quarter, Field Trip progressed its strategy of building the leading psychedelic therapy company through its Field Trip Health division and continued to invest in its lead drug development program.